Tetra Bio-Pharma: Health Canada Accepts New Drug Submission for REDUVO as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenue
OTTAWA, ON / ACCESSWIRE / June 2, 2021 /
Tetra Bio-Pharma
Inc. ( Tetra or the Company ) (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada has accepted its New Drug Submission (NDS) for REDUVO and has formally entered the final review phase in the drug review process. If successful, REDUVO will be issued a Notice of Compliance (NOC) as well as a Drug Identification Number (DIN) which permits Tetra to market the drug in Canada and indicates the drug s official approval in Canada.
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
ACCESSWIRE
This Definitive Agreement is expected to generate an excess of $
47,5M CAD
), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.
Subject to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for Reduvo™ Adversa® and QIXLEEF™, a botanical cannabinoid-derived medicine, as well as Tetra s medicinal cannabis product ENJOUCA™.
Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
ACCESSWIRE
04 May 2021, 21:43 GMT+10
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting
OTTAWA, ON / ACCESSWIRE / May 4, 2021 /
Tetra Bio-Pharma Inc. ( Tetra or the Company )(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial evaluating the safety, tolerability and potential efficacy of its veterinary ophthalmic drug, PPP-003v, in the treatment of indolent corneal ulcers in companion animals. Canine indolent corneal ulcers occur frequently in specific breeds of dogs